文献类型：期刊文献

英文题名：Severe interstitial pneumonia caused by cetuximab: a case report and review of the literature

作者：Zhou, Lan-Yun[1,2];Chen, Min-Hua[3];Shi, Jia-Na[2];Ma, Xiao-Jia[4];Mao, Xiao-Hong[2];Huang, Ping[2]

机构：[1]Shaoxing Univ, Zhuji Affiliated Hosp, Dept Pharm, Zhuji Peoples Hosp Zhejiang Prov, Zhuji, Peoples R China;[2]Zhejiang Prov Peoples Hosp, Dept Pharm, Peoples Hosp Hangzhou Med Coll, Hangzhou 310014, Peoples R China;[3]Zhejiang Prov Peoples Hosp, Dept Intens Care Unit, Peoples Hosp Hangzhou Med Coll, Hangzhou, Peoples R China;[4]Haining Second Peoples Hosp, Dept Pharm, Haining, Peoples R China

年份：2021

卷号：32

期号：10

起止页码：1123

外文期刊名：ANTI-CANCER DRUGS

收录：SCI-EXPANDED(收录号：WOS:000708619800019)、、Scopus(收录号：2-s2.0-85119303852)、WOS

语种：英文

外文关键词：cetuximab; interstitial pneumonia; oxaliplatin

外文摘要：Cetuximab is an IgG1 chimeric mAb against epidermal growth factor receptor, which can be used for chemotherapy failure or tolerance in patients with epidermal growth factor receptor expressed RAS wild-type metastatic colorectal cancer. We report on a patient who developed rapid-onset interstitial pneumonia while being treated with cetuximab plus XELOX (oxaliplatin, capecitabine) for metastatic colorectal cancer. A 75-year-old man patient was administered cetuximab plus XELOX regularly. After his cetuximab schedule was adjusted from 1 to 2 weeks, he rapidly developed interstitial pneumonia which led to acute respiratory distress syndrome. Our literature review indicated that, for patients with risk factors, a 2-week regimen of cetuximab might lead to interstitial pneumonia. Clinicians should closely monitor patients for adverse drug reactions to improve drug safety.